Inventurus Knowledge Solutions Limited, known as IKS Health, was founded in 2006 and is a top healthcare technology company. It aims to lessen the administrative burdens faced by healthcare providers. The company offers various services like clinical support, managing medical documentation, and virtual medical scribing, enabling healthcare professionals to focus more on patient care instead of paperwork. IKS Health’s innovative platform serves both outpatient facilities, which provide care without overnight stays, and inpatient settings that require longer hospital stays, catering to a wide range of patient needs. As of September 30, 2024, IKS Health partners with over 778 healthcare organizations, including major clients like Mass General Brigham Inc. and Texas Health Care PLLC. With a team of more than 13,528 employees, including over 2,600 trained health professionals, IKS Health uses technology and automation to deliver lasting benefits and results. Their strengths include a comprehensive platform that offers a variety of solutions for patients, doctors, and healthcare organizations, along with a flexible business model that emphasizes cost savings and strong engagement, improving opportunities for cross-selling in the healthcare sector.

For the year/period ended (Rs. in Cr.)

For year/ period ended ( in Cr.)

• Advanced Technology Utilization
• Tailored Solutions
• Experienced Management Team
• Strong Client Relationships
• Focus on Quality and Innovation
• Strategic Business Location

• To generate funds for business expansion and operational enhancements.
• To utilize a portion of the proceeds for repaying existing debt, improving the company’s financial health.
• To invest in advanced technologies and infrastructure to enhance service offerings.
• To increase market presence and capture a larger share in the knowledge solutions sector.
• To ensure adequate working capital for day-to-day operations and growth initiatives.

To strengthen brand recognition and visibility in the market

The company operates in niche segments as a technology-enabled healthcare solutions provider, offering a care enablement platform. The company’s topline grew at a CAGR of 34% in the last three financial years ending in March 2024. At the upper price of INR 1,329, the company is expected to list at a PE ratio of 54.7 and a PB ratio of 19.1. Considering its unique business model and the organic growth in its topline, we recommend subscribing for a long-term perspective only